Search Results - "Robinson, Shawn W"

Implementation of pharmacogenetics: The University of Maryland personalized anti-platelet pharmacogenetics program by Shuldiner, Alan R., Palmer, Kathleen, Pakyz, Ruth E., Alestock, Tameka D., Maloney, Kristin A., O'Neill, Courtney, Bhatty, Shaun, Schub, Jamie, Overby, Casey Lynnette, Horenstein, Richard B., Pollin, Toni I., Kelemen, Mark D., Beitelshees, Amber L., Robinson, Shawn W., Blitzer, Miriam G., McArdle, Patrick F., Brown, Lawrence, Jeng, Linda Jo Bone, Zhao, Richard Y., Ambulos, Nicholas, Vesely, Mark R.

“…Despite a substantial evidence base, implementation of pharmacogenetics into routine patient care has been slow due to a number of non‐trivial practical…”
Get full text

Surgical and Transcatheter Mitral Valve Repair for Severe Chronic Mitral Regurgitation: A Review of Clinical Indications and Patient Assessment by Vesely, Mark R, Benitez, R Michael, Robinson, Shawn W, Collins, Julia A, Dawood, Murtaza Y, Gammie, James S

Get full text

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention by Cavallari, Larisa H., Lee, Craig R., Beitelshees, Amber L., Cooper-DeHoff, Rhonda M., Duarte, Julio D., Voora, Deepak, Kimmel, Stephen E., McDonough, Caitrin W., Gong, Yan, Dave, Chintan V., Pratt, Victoria M., Alestock, Tameka D., Anderson, R. David, Alsip, Jorge, Ardati, Amer K., Brott, Brigitta C., Brown, Lawrence, Chumnumwat, Supatat, Clare-Salzler, Michael J., Coons, James C., Denny, Joshua C., Dillon, Chrisly, Elsey, Amanda R., Hamadeh, Issam S., Harada, Shuko, Hillegass, William B., Hines, Lindsay, Horenstein, Richard B., Howell, Lucius A., Jeng, Linda J.B., Kelemen, Mark D., Lee, Yee Ming, Magvanjav, Oyunbileg, Montasser, May, Nelson, David R., Nutescu, Edith A., Nwaba, Devon C., Pakyz, Ruth E., Palmer, Kathleen, Peterson, Josh F., Pollin, Toni I., Quinn, Alison H., Robinson, Shawn W., Schub, Jamie, Skaar, Todd C., Smith, D. Max, Sriramoju, Vindhya B., Starostik, Petr, Stys, Tomasz P., Stevenson, James M., Varunok, Nicholas, Vesely, Mark R., Wake, Dyson T., Weck, Karen E., Weitzel, Kristin W., Wilke, Russell A., Willig, James, Zhao, Richard Y., Kreutz, Rolf P., Stouffer, George A., Empey, Philip E., Limdi, Nita A., Shuldiner, Alan R., Winterstein, Almut G., Johnson, Julie A.

“…This multicenter pragmatic investigation assessed outcomes following clinical implementation of CYP2C19 genotype–guided antiplatelet therapy after percutaneous…”
Get full text

Frailty Measures of Patient-reported Activity and Fatigue May Predict 1-year Outcomes in Ambulatory Advanced Heart Failure: A Report From the REVIVAL Registry by LALA, ANURADHA, SHAH, PALAK, KHALATBARI, SHOKOUFEH, YOSEF, MATHEOS, MOUNTIS, MARIA M., ROBINSON, SHAWN W., LANFEAR, DAVID E., ESTEP, JERRY D., JEFFRIES, NEAL, TADDEI-PETERS, WENDY C., STEVENSON, LYNNE W., RICHARDS, BLAIR, MANN, DOUGLAS L., MANCINI, DONNA M., STEWART, GARRICK C., AARONSON, KEITH D.

“…The Fried Frailty Phenotype predicts adverse outcomes in geriatric populations, but has not been well-studied in advanced heart failure (HF). The Registry…”
Get full text

Comorbid Conditions and Health-Related Quality of Life in Ambulatory Heart Failure Patients: REVIVAL (Registry Evaluation of Vital Information for VADs in Ambulatory Life REVIVAL) by Cascino, Thomas M., Kittleson, Michelle M., Lala, Anuradha, Stehlik, Josef, Palardy, Maryse, Pamboukian, Salpy V., Ewald, Gregory A., Mountis, Maria M., Horstmanshof, Douglas A., Robinson, Shawn W., Shah, Palak, Jorde, Ulrich P., McLean, Rhondalyn C., Richards, Blair, Khalatbari, Shokoufeh, Spino, Cathie, Taddei-Peters, Wendy C., Grady, Kathleen L., Mann, Douglas L., Stevenson, Lynne W., Stewart, Garrick C., Aaronson, Keith D.

“…Patients with heart failure (HF) often have multiple chronic conditions that may impact health-related quality of life (HRQOL) despite HF therapy. We sought to…”
Get full text

Caregiver Health‐Related Quality of Life, Burden, and Patient Outcomes in Ambulatory Advanced Heart Failure: A Report From REVIVAL by Gilotra, Nisha A., Pamboukian, Salpy V., Mountis, Maria, Robinson, Shawn W., Kittleson, Michelle, Shah, Keyur B., Forde‐McLean, Rhondalyn C., Haas, Donald C., Horstmanshof, Douglas A., Jorde, Ulrich P., Russell, Stuart D., Taddei‐Peters, Wendy C., Jeffries, Neal, Khalatbari, Shokoufeh, Spino, Catherine A., Richards, Blair, Yosef, Matheos, Mann, Douglas L., Stewart, Garrick C., Aaronson, Keith D., Grady, Kathleen L.

Get full text

A Genome-Wide Association Study of Idiopathic Dilated Cardiomyopathy in African Americans by Xu, Huichun, Dorn, 2nd, Gerald W, Shetty, Amol, Parihar, Ankita, Dave, Tushar, Robinson, Shawn W, Gottlieb, Stephen S, Donahue, Mark P, Tomaselli, Gordon F, Kraus, William E, Mitchell, Braxton D, Liggett, Stephen B

“…Idiopathic dilated cardiomyopathy (IDC) is the most common form of non-ischemic chronic heart failure. Despite the higher prevalence of IDC in African…”
Get full text

A New Clinically Applicable Measure of Functional Status in Patients With Heart Failure: The 60-Foot Walk Test by Harris, Kristie M, Krantz, David S, Kop, Willem J, Marshall, Joanne, Robinson, Shawn W, Marshall, Jennifer M, Gottlieb, Stephen S

“…This study reports the development and predictive value of the 60-foot walk test (60ftWT), a brief functional status measure for patients with heart failure…”
Get full text

An Antisense Oligonucleotide Against H1 Inhibits the Classical Sodium Current but not ICa(TTX) in Rat Ventricular Cells by Sha, Qun, Robinson, Shawn W., McCulle, Stacey L., Shorofsky, Stephen R., Welling, Paul A., Goldman, L., Balke, C. William

“…I Ca(TTX) is a sodium current component, functionally distinct from the main body of sodium current, seen in cardiac and other cells. To determine if I Ca(TTX)…”
Get full text

Factors Associated with Chronic Worsening of Renal Function in Stable Heart Failure Patients in an Ambulatory Setting by Robinson, Shawn W, Gottlieb, Stephen S, Marshall, Joanne, Poliakova, Liobov, Sarwate, Devadatta

Get full text

A New Clinically Applicable Measure of Functional Status in Patients With Heart Failure by Harris, Kristie M., MS, Krantz, David S., PhD, Kop, Willem J., PhD, Marshall, Joanne, RN, MSN, Robinson, Shawn W., MD, Marshall, Jennifer M., BS, Gottlieb, Stephen S., MD

“…Abstract Objectives This study reports the development and predictive value of the 60-foot walk test (60ftWT), a brief functional status measure for patients…”
Get full text

Hypertrophy-Associated Polymorphisms Ascertained in a Founder Cohort Applied to Heart Failure Risk and Mortality by Parsa, Afshin, Chang, Yen-Pei C., Kelly, Reagan J., Corretti, Mary C., Ryan, Kathleen A., Robinson, Shawn W., Gottlieb, Stephen S., Kardia, Sharon L.R., Shuldiner, Alan R., Liggett, Stephen B.

“…A three‐stage approach was undertaken using genome‐wide, case‐control, and case‐only association studies to identify genetic variants associated with heart…”
Get full text

Sex, Digitalis, and the Sodium Pump by Blaustein, Mordecai P, Robinson, Shawn W, Gottlieb, Stephen S, Balke, C William, Hamlyn, John M

“…Foxglove and its constituents therapeutic agent digitalis have been used for centuries for the treatment of heart failure. All digitalis-like cardiotonic…”
Get full text

The Association of Sodium Intake and Objective and Subjective Indicators of Heart Failure Severity by Harris, Kristie M, Wawrzyniak, Andrew J, Marshall, Jennifer M, Godoy, Sarah M, Marshall, Joanne P, Robinson, Shawn W, Krantz, David S, Gottlieb, Stephen S

Get full text

Stimulation of Na,K-ATPase by low potassium requires reactive oxygen species by Zhou, Xiaoming, Yin, Wu, Doi, Sonia Q, Robinson, Shawn W, Takeyasu, Kunio, Fan, Xuetao

“…The signaling pathway that transduces the stimulatory effect of low K+ on the biosynthesis of Na,K-ATPase remains largely unknown. The present study was…”
Get more information

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation by Shuldiner, A R, Relling, M V, Peterson, J F, Hicks, K, Freimuth, R R, Sadee, W, Pereira, N L, Roden, D M, Johnson, J A, Klein, T E

“…The pace of discovery of potentially actionable pharmacogenetic variants has increased dramatically in recent years. However, the implementation of this new…”
Get full text

Abstract 16631: Frailty Phenotype is Associated With 1-Year Outcomes in Ambulatory Advanced Heart Failure: A Report From the REVIVAL Registry by Lala, Anuradha, Shah, Palak, Cooper, Lauren, Mountis, Maria, Robinson, Shawn W, Lanfear, David, Estep, Jerry D, Jorde, Urlich, Jeffries, Neal, Stevenson, Lynne W, Khalatbari, Shokoufeh, Spino, Catherine A, Richards, Blair, Mann, Douglas, Stewart, Garrick C, Aaronson, Keith D

“…IntroductionThe Fried Frailty Phenotype (FFP), defined by weakness, slowness, inactivity, exhaustion and weight loss, predicts adverse outcomes in geriatric…”
Get full text

Abstract 17088: Role of Caregiver Participation in Outcomes for Patients With Advanced Ambulatory Heart Failure: An Analysis of the Revival Registry by Gilotra, Nisha A, Robinson, Shawn W, Kittleson, Michelle, Shah, Keyur, Pamboukian, Salpy, Haas, Donald C, Horstmanshof, Douglas A, McNamara, Dennis, Forde-McLean, Rhondalyn, Taddei-Peters, Wendy C, Khalatbari, Shokoufeh, Spino, Catherine A, Richards, Blair, Mann, Douglas L, Stevenson, Lynne W, Stewart, Garrick C, Aaronson, Keith D

“…IntroductionAdvanced HF requires tremendous resources, and family caregivers generate significant health related cost-savings. Earlier work in the REVIVAL…”
Get full text

Comorbid Conditions and Health-related Quality of Life in Ambulatory Heart Failure Patients: A Report from REVIVAL by Cascino, Thomas M., Kittleson, Michelle M., Lala, Anuradha, Stehlik, Josef, Palardy, Maryse, Pamboukian, Salpy V., Ewald, Gregory A., Mountis, Maria M., Horstmanshof, Douglas A., Robinson, Shawn W., Shah, Palak, Jorde, Ulrich P., McLean, Rhondalyn C., Richards, Blair, Khalatbari, Shokoufeh, Spino, Cathie, Taddei-Peters, Wendy C., Grady, Kathleen L., Mann, Douglas L., Stevenson, Lynne W., Stewart, Garrick C., Aaronson, Keith D.

Get full text

Multi-site Investigation of Outcomes with Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy after Percutaneous Coronary Intervention by Cavallari, Larisa H., Lee, Craig R., Beitelshees, Amber L., Cooper-DeHoff, Rhonda M., Duarte, Julio D., Voora, Deepak, Kimmel, Stephen E., McDonough, Caitrin W., Gong, Yan, Dave, Chintan V., Pratt, Victoria M., Alestock, Tameka D., Anderson, R. David, Alsip, Jorge, Ardati, Amer K., Brott, Brigitta C., Brown, Lawrence, Chumnumwat, Supatat, Clare-Salzler, Michael J., Coons, James C., Denny, Joshua C., Dillon, Chrisly, Elsey, Amanda R., Hamadeh, Issam, Harada, Shuko, Hillegass, William B., Hines, Lindsay, Horenstein, Richard B., Howell, Lucius A., Jeng, Linda J.B., Kelemen, Mark D., Lee, Y.M., Magvanjav, Oyunbileg, Montasser, May, Nelson, David R., Nutescu, Edith A., Nwaba, Devon C., Pakyz, Ruth E., Palmer, Kathleen, Peterson, Josh F., Pollin, Toni I., Quinn, Alison H., Robinson, Shawn W., Schub, Jamie, Skaar, Todd C., Smith, Donald M., Sriramoju, Vindhya B., Starostik, Petr, Stys, Tomasz P., Stevenson, James M., Varunok, Nicholas, Vesely, Mark R., Wake, Dyson T., Weck, Karen E., Weitzel, Kristin W., Wilke, Russell A., Willig, James, Zhao, Richard Y., Kreutz, Rolf P., Stouffer, George A., Empey, Philip E., Limdi, Nita A., Shuldiner, Alan R., Winterstein, Almut G., Johnson, Julie A.

Get full text